✦ LIBER ✦

193 Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)

✍ Scribed by C. Saura; H. Burris; C.L. Arteaga; I. Mayer; C. Germa; N. Fretault; D. Sternberg; L. Trandafir; C. Massacesi; J. Rodon

Book ID: 117662103
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 63 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(12)70261-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, Dose-Escalation Study of BKM120

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

✍ Bendell, J. C.; Rodon, J.; Burris, H. A.; de Jonge, M.; Verweij, J.; Birle, D.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB

Phase I dose-escalation and -expansion s

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

✍ Rodon, Jordi; Braña, Irene; Siu, Lillian L; Jonge, Maja J; Homji, Natasha; Mills 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 925 KB

565 Phase I combination study of oral vi

565 Phase I combination study of oral vinorelbine (VRL) and oral cyclophosphamide (CTX) in patients with metastatic breast cancer (MBC)

✍ A.J. ten Tije; C. Seynaeve; J.H. Schornagel; J.C. Pouget; B. Laffranchi; G. Blan 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Phase I/II trial of oral UFT/Leucovorin

Phase I/II trial of oral UFT/Leucovorin (LV) and paclitaxel (P) in the second line treatment of patients (PTS) with metastatic breast cancer (MBC)

✍ Klaassen, U.; Lang, S.; Borquez, D.; Oberhoff, C.; Benner, S.; Harstrick, A.; Se 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 322 KB

Phase I Trial of the Cyclin-Dependent Ki

Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Docetaxel in Patients With Metastatic Breast Cancer

✍ Nahta, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Phase I trial of oral mTOR inhibitor eve

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

✍ Guy Jerusalem; Angelica Fasolo; Veronique Dieras; Fatima Cardoso; Jonas Bergh; L 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 326 KB